BioLargo (BLGO) & The Competition Head-To-Head Review

BioLargo (NASDAQ:BLGO) is one of 34 publicly-traded companies in the “Chemicals & allied products” industry, but how does it compare to its peers? We will compare BioLargo to similar businesses based on the strength of its earnings, risk, analyst recommendations, dividends, valuation, institutional ownership and profitability.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for BioLargo and its peers, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioLargo	0	0	0	0	N/A
BioLargo Competitors	139	1268	1590	46	2.51

As a group, “Chemicals & allied products” companies have a potential upside of 9.09%. Given BioLargo’s peers higher possible upside, analysts plainly believe BioLargo has less favorable growth aspects than its peers.

Insider and Institutional Ownership

0.0% of BioLargo shares are owned by institutional investors. Comparatively, 68.4% of shares of all “Chemicals & allied products” companies are owned by institutional investors. 20.3% of BioLargo shares are owned by company insiders. Comparatively, 10.1% of shares of all “Chemicals & allied products” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares BioLargo and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
BioLargo	-16.53%	-58.35%	-32.12%
BioLargo Competitors	-568.74%	5.73%	-0.15%

Earnings & Valuation

This table compares BioLargo and its peers gross revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
BioLargo	$12.23 million	-$3.50 million	-8.10
BioLargo Competitors	$6.65 billion	$206.77 million	62.52

BioLargo’s peers have higher revenue and earnings than BioLargo. BioLargo is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Risk and Volatility

BioLargo has a beta of 0.2, meaning that its share price is 80% less volatile than the S&P 500. Comparatively, BioLargo’s peers have a beta of 1.78, meaning that their average share price is 78% more volatile than the S&P 500.

Summary

BioLargo peers beat BioLargo on 7 of the 9 factors compared.

About BioLargo

BioLargo, Inc. invents, develops, and commercializes various platform technologies. Its technologies solve challenging environmental problems comprising per – and polyfluoroalkyl substances (PFAS) water contamination, advanced water and wastewater treatment, industrial odor and volatile organic compounds control, air quality control, infection control, and myriad environmental remediation. The company provides full-service environmental engineering services. BioLargo, Inc. was incorporated in 1991 and is based in Westminster, California.